Protara Therapeutics (TARA) Competitors $3.11 +0.01 (+0.32%) Closing price 04:00 PM EasternExtended Trading$3.10 -0.01 (-0.32%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARA vs. KURA, PRME, ARVN, ETON, SVRA, PVLA, ITOS, SNDL, CGEM, and CMPSShould you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Kura Oncology (KURA), Prime Medicine (PRME), Arvinas (ARVN), Eton Pharmaceuticals (ETON), Savara (SVRA), Palvella Therapeutics (PVLA), iTeos Therapeutics (ITOS), SNDL (SNDL), Cullinan Therapeutics (CGEM), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Protara Therapeutics vs. Its Competitors Kura Oncology Prime Medicine Arvinas Eton Pharmaceuticals Savara Palvella Therapeutics iTeos Therapeutics SNDL Cullinan Therapeutics COMPASS Pathways Kura Oncology (NASDAQ:KURA) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Does the media favor KURA or TARA? In the previous week, Protara Therapeutics had 4 more articles in the media than Kura Oncology. MarketBeat recorded 9 mentions for Protara Therapeutics and 5 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.74 beat Protara Therapeutics' score of 0.62 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, KURA or TARA? Protara Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura Oncology$83.28M7.97-$173.98M-$2.26-3.38Protara TherapeuticsN/AN/A-$44.60M-$1.62-1.92 Do analysts recommend KURA or TARA? Kura Oncology presently has a consensus price target of $24.10, suggesting a potential upside of 215.03%. Protara Therapeutics has a consensus price target of $19.60, suggesting a potential upside of 530.23%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Kura Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86Protara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do institutionals & insiders hold more shares of KURA or TARA? 38.1% of Protara Therapeutics shares are owned by institutional investors. 6.4% of Kura Oncology shares are owned by insiders. Comparatively, 8.4% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, KURA or TARA? Kura Oncology has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Is KURA or TARA more profitable? Protara Therapeutics' return on equity of -36.87% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -52.32% -29.59% Protara Therapeutics N/A -36.87%-33.85% SummaryProtara Therapeutics beats Kura Oncology on 10 of the 14 factors compared between the two stocks. Get Protara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARA vs. The Competition Export to ExcelMetricProtara TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.98M$2.80B$5.82B$9.74BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-1.9222.6131.1525.97Price / SalesN/A751.86475.57123.18Price / CashN/A173.2237.1558.38Price / Book0.835.869.116.39Net Income-$44.60M$31.83M$3.26B$265.66M7 Day Performance2.64%1.80%2.11%1.98%1 Month Performance-6.61%4.36%5.12%1.33%1 Year Performance46.01%11.44%31.25%21.15% Protara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARAProtara Therapeutics1.8714 of 5 stars$3.11+0.3%$19.60+530.2%+44.2%$119.98MN/A-1.9230News CoverageAnalyst RevisionKURAKura Oncology3.9658 of 5 stars$5.54flat$24.10+335.0%-62.7%$480.86M$53.88M-2.45130Gap UpPRMEPrime Medicine2.9212 of 5 stars$3.51-7.4%$8.92+154.0%-26.8%$472.08M$4.96M-1.71234Gap UpARVNArvinas4.109 of 5 stars$6.59+4.8%$19.76+199.9%-71.0%$461.80M$263.40M-6.52420Positive NewsETONEton Pharmaceuticals2.4186 of 5 stars$17.05-0.5%$29.67+74.0%+312.8%$459.65M$39.01M-106.5620Positive NewsInsider TradeSVRASavara3.3596 of 5 stars$2.70+2.3%$5.60+107.4%-31.9%$456.29MN/A-5.6220PVLAPalvella Therapeutics1.9697 of 5 stars$41.71+2.0%$52.40+25.6%N/A$452.18M$42.81M-3.45N/ANews CoverageAnalyst ForecastITOSiTeos Therapeutics2.4092 of 5 stars$10.11flat$15.50+53.3%-41.7%$446.92M$35M-2.1690SNDLSNDL1.8281 of 5 stars$2.01+19.3%$4.00+99.5%+6.2%$441.46M$671.81M-7.432,516High Trading VolumeCGEMCullinan Therapeutics1.7856 of 5 stars$7.09-2.9%$30.00+323.1%-57.4%$430.95MN/A-2.2030News CoverageAnalyst ForecastAnalyst RevisionCMPSCOMPASS Pathways2.6396 of 5 stars$4.34-1.1%$16.29+275.2%-38.8%$421.18MN/A-2.36120 Related Companies and Tools Related Companies KURA Alternatives PRME Alternatives ARVN Alternatives ETON Alternatives SVRA Alternatives PVLA Alternatives ITOS Alternatives SNDL Alternatives CGEM Alternatives CMPS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access